Fig. 5
From: Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
BI-880 overcomes anti-VEGF resistance in LLC tumours. a Schematic depicting treatment schedule. b Tumour growth of syngeneic LLC tumours subjected to vehicle, anti-VEGF (B20), anti-VEGF/anti-Ang2 (B20/BI-880) or anti-VEGF/anti-neutrophil (B20/anti-Ly6G antibody) treatment. c Representative 100× images depicting vascularisation of LLC tumour sections stained with FITC-CD31 (green) and quantification of vessel density. d Images of xenograft-infiltrating neutrophils (Ly6G/C red, 100×) and quantification thereof. e H&E staining of tumour sections and quantification of tumour necrosis (scale bar 2000 µm); *p < 0.05. **p < 0.01, n.s. not significant
